What did Nanosonics (ASX:NAN) announce regarding its CORIS system?

Nanosonics has received 510(k) clearance from the US FDA for the first round of expanded endoscope indications for its CORIS platform. This regulatory approval allows the automated disinfection system to be used on a wider variety of flexible endoscopes than previously authorised under its initial De Novo clearance.

Why is this FDA 510(k) clearance significant for Nanosonics (ASX:NAN) investors?

This clearance validates CORIS as "substantially equivalent" to legally marketed products while broadening its clinical utility in the critical US market. By expanding the range of compatible endoscopes, Nanosonics increases the total addressable market for the device, which is specifically designed to clean difficult internal channels where dangerous biofilms persist

How does this news change the long-term investment thesis for Nanosonics (ASX:NAN)?

The approval confirms that Nanosonics is meeting its regulatory milestones, reducing the execution risk associated with the CORIS product launch. It supports the company’s transition from a single-product business (focused on the Trophon ultrasound probe disinfector) to a multi-platform infection prevention company with a larger global footprint.

What is the expected timeline for the full global rollout of CORIS?

Management has scheduled the full global commercial rollout of the CORIS system for FY27. This follows a phased strategy intended to ensure product reliability and market readiness before a large-scale capital equipment launch.

What are the current "controlled market release" (CMR) activities for Nanosonics?

Nanosonics has already commenced a controlled market release of CORIS in the UK to gather real-world performance data. The company plans to expand this limited release shortly to include additional sites in Australia, Ireland, and the United States.

What are the main bull points for Nanosonics (ASX:NAN) following this announcement?

The bull case rests on the successful expansion of FDA indications, which creates a clearer path to revenue in FY27. Additionally, the CORIS system addresses a major pain point in healthcare—hospital-acquired infections—positioning Nanosonics as a leader in a high-stakes, defensive medical technology niche.

What are the key bear points or risks for Nanosonics (ASX:NAN) traders to watch?

The primary risk is the long lead time, as a full commercial rollout is not expected until FY27, leaving a significant gap where the company must fund ongoing development. There is also the potential for further regulatory hurdles or slower-than-expected adoption by hospitals during the controlled market release phase.

Image for illustrative purposes only. Not a real photo.

Nanosonics secures crucial FDA CORIS clearance

Written by Mahathir BayenaPublished Mar 9, 2026, 5:30 AMLast Updated Jul 6, 2026, 5:26 AM

Nanosonics (ASX:NAN) announced that the US Food and Drug Administration has granted 510(k) clearance for the first round of expanded endoscope indications for its innovative CORIS system.

The milestone marks a leap forward in the company's mission to revolutionise medical device reprocessing and reduce hospital-acquired infections.

Building upon the initial De Novo clearance previously granted for CORIS, this new 510(k) authorisation validates the system as "substantially equivalent" to legally marketed products while broadening its clinical utility.

The clearance immediately increases the variety of flexible endoscopes that can be processed using the automated system, which is specifically designed to tackle the difficult-to-clean internal channels where dangerous biofilms often persist.

"This first FDA 510(k) clearance keeps us tracking to plan as we execute against our key milestones," said Nanosonics CEO and President Michael Kavanagh.

He noted that the approval builds vital momentum for upcoming commercial activities, with a full global rollout scheduled for FY27.

Currently, a controlled market release is underway in the UK, with additional sites in Australia, Ireland, and the United States expected to follow shortly.

At the time of reporting, Nanosonics' share price was $3.69.

Nanosonics secures crucial FDA CORIS clearance

Perguntas frequentes

Ativos relacionados a notícia